Brentuximab Vedotin

Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial drug plans and cancer agencies. This review assesses BrECADD; the key drug in the combination is brentuximab vedotin (IV). Indication under consideration for reimbursement: Treatment of adult patients with newly diagnosed, advanced-stage, classical Hodgkin lymphoma.